Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Hata, Niederstet al. present data suggesting that genetic resistance to the epidermal growth factor receptor (EGFR) inhibitor gefitinib can develop either through selection of clones carrying a pre-existing resistance mutation, or through the eventual de novodevelopment of a resistance mutation in cells that survive initial therapy.
Roybalet al. have designed a system in which two tumour antigens are required to effectively induce T cell activation through chimeric antigen receptors, which in principle could improve the efficacy and safety of T cell therapies.
Interferons (IFNs) activate and regulate antitumour immune responses. This Review discusses lessons that can be learnt from using type I IFNs in oncology and our current understanding of the interferome in modifying antitumour immune responses.
This Review discusses the molecular biology underlying chronic lymphocytic leukaemia (CLL). Emphasizing the role of genetic lesions in CLL initiation and clinical progression, the article also considers the clinical implications of these findings.
One interesting theme in the history of cancer research is the extent to which new biological insights and novel clinical applications have their origins in haematopoietic cancers. This Timeline article examines the roles that studies in leukaemia have had in this progress.
This Opinion article summarizes the evidence supporting the use of aspirin to prevent colorectal cancer. By considering the pathways that mediate the anticancer effects of aspirin, the authors evaluate potential biomarkers that may enable a precision medicine approach to aspirin chemoprevention.
This Opinion article discusses the opportunities and challenges for 'precision mouse modelling', including the proposed essential criteria of mouse models for prevention research, representative success stories and opportunities for improved analyses in future studies of precision cancer prevention.
